Trials / Withdrawn

WithdrawnNCT01239017

A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee

A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Single Dose Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee

Status: Withdrawn
Phase: Phase 2
Study type: Interventional
Enrollment: 0 (actual)

Sponsor: Regeneron Pharmaceuticals · Industry
Sex: All
Age: 40 Years – 75 Years
Healthy volunteers: Not accepted

Summary

This is a double-blind, prospective, randomized study in which patients will be randomized to 1 of 5 treatment arms (4 active and 1 placebo). Each patient will receive one SC injection of REGN475 or placebo and 1 IV infusion of either REGN475 or placebo, on day 1 (baseline) In order to preserve the blind, patients receiving REGN475 SC will also receive placebo IV, and patients receiving REGN475 IV will also receive placebo SC.

Conditions

Osteoarthritis

Interventions

Type	Name	Description
BIOLOGICAL	REGN475
OTHER	Placebo

Timeline

First posted: 2010-11-11
Last updated: 2015-03-18

Source: ClinicalTrials.gov record NCT01239017. Inclusion in this directory is not an endorsement.